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Abstract
The treatment outcomes of follicular lymphoma (FL) patients have been positively inﬂuenced by the intro-
duction of rituximab in the last 2 decades. A retrospective analysis of progression-free survival and overall
survival of 278 routinely treated Slovene FL patients conﬁrmed the signiﬁcant beneﬁt of adding rituximab to
chemotherapy and into the maintenance setting outside clinical studies.
Background: The outcome of follicular lymphoma (FL) patients has dramatically improved over the last 2 decades by
introduction of rituximab in combination chemotherapy and into maintenance setting. We retrospectively analyzed the
treatment outcomes in Slovene FL patients in the era of rituximab and compared them to the results reported by
pivotal clinical studies. Patients and Methods: Two hundred seventy-eight patients with FL treated in Slovenia be-
tween 2000 and 2010 with a median follow-up of 5.7 years were included in our retrospective analysis. One hundred
ninety-three (69%) received systemic treatment (ST). Results:With a median follow-up of 5.7 years, the 5- and 10-year
overall survival (OS) rates for the whole series were 77% and 53%, respectively. The 5-year progression-free survival
(PFS) for 193 FL patients treated with ST was 37%. Patients treated with rituximab chemotherapy had a signiﬁcantly
better OS than patients treated with chemotherapy alone, with a 5-year OS of 79% versus 53% (hazard ratio [HR],
0.39; 95% conﬁdence interval [CI], 0.22-0.67; P ¼ .001). Adding rituximab to the ﬁrst-line chemotherapy signiﬁcantly
improved PFS compared to chemotherapy alone (HR, 0.26; 95% CI 0.18-0.36; P < .001). Maintenance rituximab after
immunochemotherapy in ﬁrst-line treatment reduced the risk for progression by 61% and signiﬁcantly prolonged the
time to progression (HR, 0.39; 95% CI 0.20-0.73; P < .003). Conclusion: The outcomes in our routinely treated FL
patients conﬁrm the beneﬁt of adding rituximab to chemotherapy and are comparable to the results of pivotal clinical
studies. The outcome of our FL patients was improved in terms of both PFS and OS.
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Follicular lymphoma (FL) is the second most common subtype of
non-Hodgkin lymphoma, comprising 20% to 30% of all lym-
phomas and approximately 70% of indolent lymphomas. The
median age at diagnosis is 60 years. Clinically, the disease is char-
acterized by an indolent course, with waxing and waning lymph-
adenopathy, slowly progressing over the years. Most patients are
diagnosed with advanced-stage disease; despite the major progress
that has been made in the management of the disease, it is still
considered incurable.1,2Division of Medical Oncology, Institute of Oncology Ljubljana, Ljubljana, Slovenia
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Current treatment approaches vary from watchful waiting to
combination chemotherapy and allogeneic transplantation.3 The
watch-and-wait strategy remains a safe option for patients without
disease-related symptoms because randomized studies have not
demonstrated a survival beneﬁt with early application of systemic
therapy.4 With the introduction of the anti-CD20 monoclonal
antibody rituximab, the prognosis of FL patients has dramatically
changed over the past 2 decades. The beneﬁt of adding rituximab to
combination chemotherapy has been proved in multiple randomized
trials, all of which demonstrated improvement in response rates, time
to progression, and improvement in survival.5-9 Additional beneﬁt in
the outcome of FL patients has been proven by introduction of rit-
uximab in the maintenance setting. Several prospective randomized
studies have shown the beneﬁcial effect of rituximab maintenance
therapy in patients with previously untreated and relapsed FL.10-14
The results of the PRIMA study established rituximab maintenance2152-2650/ª 2015 The Authors. Published by Elsevier Inc. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Table 1 Patient Characteristics
Characteristic
All Patients
(n [ 278)
Patients With ST
(n [ 193)
Age (Years)
60, n (%) 128 (46.1) 87 (45.0)
Median (range) 58 (20-90) 57 (20-90)
Gender, n (%)
Male 113 (40.6) 78 (40.0)
Female 165 (59.4) 115 (60.0)
Stage, n (%)
I 53 (19.1) 15 (7.7)
II 43 (15.5) 27 (14.0)
III 53 (19.1) 36 (18.6)
IV 127 (45.7) 114 (59.0)
Not determined 2 1
Grade, n (%)
1 35 (12.6) 24 (12.4)
2 105 (37.8) 68 (35.2)
3 76 (27.3) 53 (27.4)
FL þ DVCBL 14 (5.0) 14 (7.2)
Not determined 48 (17.3) 34
FLIPI Score, n (%)
Low (0-1) 125 (44.9) 62 (32.0)
Intermediate (2) 72 (25.9) 59 (30.5)
High (3-5) 74 (26.6) 67 (34.7)
Not determined 7 5
Abbreviations: FL þ DLBCL ¼ follicular lymphoma þ diffuse large B cell lymphoma;
FLIPI ¼ Follicular Lymphoma International Prognostic Index; ST ¼ systemic treatment.therapy as a new standard of care for the ﬁrst-line treatment of
patients who experience remission after immunochemotherapy.15
With the modern rituximab chemotherapeutic regimens, the
median survival of FL patients has been prolonged from 8 to 10
years to 12 to 15 years.3,16-18 Hence, the introduction of rituximab
into therapy represents an important step forward in the manage-
ment of this disease and has become the standard of care in ﬁrst-
line, relapse, and maintenance treatment of FL patients.19
According to cancer registry data, Slovenia has about 65 new
cases of FL per year, with an incidence rate of 2.8 per 100,000
persons for both men and women, which represents approximately
20% of all non-Hodgkin lymphoma cases in Slovenia.20
The aim of our retrospective study of 278 FL patients was to
analyze the treatment outcome in Slovene FL patients, to evaluate
the beneﬁt of adding rituximab to combination therapy, and to
compare the results to the outcomes of FL patients reported by
major clinical studies.
Patients and Methods
Patients
Two hundred seventy-eight patients diagnosed with FL treated at
the Institute of Oncology and other Slovene hospitals between 2000
and 2010 were included in our retrospective analysis.
Methods
Treatment decisions were based primarily on consensus recom-
mendations at the time. After the completion of primary treatment,
patients underwent regular follow-up examinations at our institute.
Patient and disease characteristics, treatment, and survival outcomes
were evaluated retrospectively from patients’ records. All procedures
were compliant with the ethical standards of the local institutional
ethical committee.
Statistical Analysis
The outcome variables analyzed were progression-free survival
(PFS) and overall survival (OS), deﬁned according to the criteria of
Cheson et al.21 The PFS was calculated from the date of starting
treatment to the ﬁrst occurrence of relapse, disease progression or
death, or last follow-up. OS was deﬁned as the time interval be-
tween the date of diagnosis of lymphoma and last follow-up or
death. Survival curves were plotted by the Kaplan-Meier method,
and the log rank test was applied to analyze statistical differences in
survival.22 Cox multivariate hazard models were used to calculate
the hazard ratios (HR) and their 95% conﬁdence intervals (CI) in
the analysis of PFS and OS. All reported P values are 2-tailed. SPSS
version 19.0 was used for all statistical analysis (IBM, Armonk, NY).
Results
Patient Characteristics and Treatment
Baseline characteristics are presented in Table 1. A total of 278
patients with FL were included in our analysis. The median age was
58 years; 128 patients (46.1%) were older than 60 years. There were
59.4% women and 40.6% men included. Thirty-four percent of the
patients had limited-stage disease, and almost 65% had advanced-
stage disease at the time of diagnosis. According to histopatholog-
ic grade, 50% had low-grade FL (grade 1 or 2), 27.3% were grade 3,
and 5% were combined FL and diffuse large B-cell lymphoma. In48 patients, the grade was not deﬁned. According to Follicular
Lymphoma International Prognostic Index (FLIPI) score, 45% were
considered low risk, 26% intermediate risk, and 26.6% high risk.
One hundred ninety-three of all patients who needed therapy
received systemic treatment (ST). The induction regimen was R-
CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and
prednisone) in 54.4%, 4 patients received R-CVP (rituximab,
cyclophosphamide, doxorubicin, vincristine), and 2 patients received
rituximab combined with other chemotherapy regimens. The other
82 patients (42.5%) received chemotherapy alone as an induction
regimen, with CHOP (n ¼ 26) and CVP (n ¼ 39) being the regi-
mens most often provided. Seventeen patients received chlorambucil.
Among 111 patients who received rituximab chemotherapy as ﬁrst-
line treatment, 66 continued with maintenance rituximab. There
were no statistically signiﬁcant differences regarding grade, stage, and
FLIPI between the maintenance rituximab and observation groups.
Altogether, 163 FL patients received rituximab chemotherapy at
least once in their lifetime during the course of their disease as ﬁrst-
line treatment or in a relapse setting, and only 30 patients had never
been treated with rituximab.
Disease Outcomes
OS of All Patients (n ¼ 278) and OS of Patients Treated With
Systemic Therapy (n ¼ 193). With a median follow-up of 5.7 years
(range, 2-11 years), the estimated 5- and 10-year OS rates for theClinical Lymphoma, Myeloma & Leukemia October 2015 - 587
Figure 2 Progression-Free Survival of 193 Follicular
Lymphoma Patients Treated With Systemic Therapy
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588 -whole series were 77% and 53%, respectively. The median OS has
not yet been reached. The respective OS rates of 193 patients
treated with ST were 75% and 48%, with a median OS of 9.43
years (Figure 1).
PFS of Patients Treated With Systemic Therapy (n ¼ 193). The
3- and 5-year PFS of 193 patients treated with ﬁrst-line ST were
47% and 37%, respectively. The median PFS was 2.3 years (95%
CI, 1.4-3.1) (Figure 2).
PFS and OS of FL Patients According to Rituximab in First-Line
Therapy (n ¼ 193). The 3- and 5-year PFS rates of 82 patients
treated with chemotherapy alone in ﬁrst-line treatment were 20% and
14%, respectively. The 3- and 5-year PFS of the 111 patients treated
with rituximab chemotherapy in ﬁrst-line were 69% and 54%,
respectively. The median survival has not yet been reached in
the rituximab chemotherapy group and was 12 months in the
chemotherapy-alone group. The risk of progression of FL in patients
treated with rituximab chemotherapy was reduced by 74% compared
to patients treated with chemotherapy alone (HR, 0.26; 95% CI,
0.18-0.36; P < .001) (Figure 3A).
The 3- and 5-year OS rates of 193 patients according to ﬁrst-line
rituximab treatment was 82% for both for the rituximab chemo-
therapy group, and 82% and 68% for the chemotherapy-alone
group. The difference was not statistically signiﬁcant (HR, 0.76;
95% CI, 0.45-1.27; P ¼ .29) (Figure 3B).
PFS of FL Patients According to Maintenance Rituximab Versus
Observation in First-Line Immunochemotherapy (n ¼ 111). The
3- and 5-year PFS rates of 66 patients treated with maintenance
rituximab in ﬁrst-line immunochemotherapy were 77% and 64%,
respectively, whereas the respective PFS rates for the observationFigure 1 Overall Survival of All Patients and Patients Treated
With Systemic Therapy (ST)
Clinical Lymphoma, Myeloma & Leukemia October 2015group were 50% and 39%. The median PFS has not been reached
in the maintenance rituximab group and was 3.2 years in the
observation group. Treatment with maintenance rituximab after
immunochemotherapy reduced the risk of progression for 61%
compared to the observation group (HR, 0.39; 95% CI, 0.20-0.73;
P ¼ .003) (Figure 4).
OS of FL Patients Treated With Rituximab Chemotherapy as First-
Line Treatment or in Relapse Versus Chemotherapy Alone (n ¼ 193).
The estimated 5- and 10-year OS rates of 163 FL patients treated
with rituximab chemotherapy at least once during the course of
disease were 79% and 52%, respectively. The 5- and 10-year OS
estimates for 30 patients who had never received rituximab-
containing therapy were 53% and 29%, respectively. The risk of
dying was reduced by 61% in the rituximab-treated group (HR,
0.39; 95% CI, 0.22-0.67; P ¼ .001) (Figure 5).
Discussion
FL is an indolent disease, so patients may have a long life expec-
tancy, but it is still considered incurable in its advanced stage. Patients
usually respond well to initial therapy, but relapses are common,
leading to recurrent therapeutic interventions. Despite decades of
study, no uniformly accepted standard initial treatment has emerged
for patients with FL. For patients without disease-related symptoms, a
watch-and-wait strategy is still a safe option. Those who develop
systemic symptoms or have high tumor burden need to initiate
treatment. With the introduction of the anti-CD20 monoclonal
antibody rituximab into therapy, the clinical outcome of FL patients
has markedly improved.
The clinical characteristics of our patients do not differ from
those described in other studies and from the report of a Lym-
phoCare study.3 The median age of our patients was 58 years, and
Figure 3 Progression-Free Survival (A) and Overall Survival (B) According to Rituximab in First-Line Therapy
Figure 4 Progression-Free Survival According to Maintenance
Rituximab Versus Observation in First-Line
Immunochemotherapy
Tanja Juznic Setina et alwe observed a slight female predominance. Most of the patients
(65%) were diagnosed with advanced-stage disease, which is a little
less frequently than what is described in the literature. The distri-
bution of FLIPI groups was similar to that described in other
studies, with most patients being in low and intermediate FLIPI risk
groups.
At a median follow-up of 5.7 years, the 5-year OS of the whole
group was 77% and is similar to the data of the EUROCARE-5
study from the period 1997 to 2008, with a reported 5-year sur-
vival rate of 74.3% (72.9%-75.5%).23 On the other hand, the
analysis by Fisher et al16 describes a 4-year survival rate of 69% for
CHOP and up to 91% for the R-CHOP studies, yet the outcomes
are given only for the patients treated with systemic therapy and not
for the complete cohort of FL patients.
In 193 patients, ST was implemented. Those patients differed
from the whole group of 278 patients in that more patients had
stage IV disease and more patients had intermediate and high FLIPI
scores. Interestingly, the OS rates of the whole group and the group
receiving ST were very similar.
The PFS curve of the patients who received ST, 57% of them
with rituximab, is consistent with the progressing course of the
disease. Still, the 5-year PFS of 37% is in concordance with the 40%
5-year PFS reported for 832 patients in the observational study
conducted to develop the FLIPI 2 prognostic index, where 68% of
patients received a rituximab chemotherapyebased regimen.24
Several randomized phase 3 trials have demonstrated improved
survival rates by adding rituximab to standard chemotherapy in front-
line treatment of FL patients. Almost all of them demonstrated
improved PFS with rituximab plus chemotherapy, with some of them
also experiencing improved OS.5-9,25 Most of these trials applied
R-CHOP, R-CVP, or R-FM (rituximab, ﬂudarabine, mitoxantrone)as front-line chemotherapy. Other chemotherapy drugs, such as
bendamustine plus rituximab, have been evaluated in a randomized
trial with signiﬁcantly improved PFS and proven noninferiority to
previously mentioned regimens but with no difference in OS.25 A
recently published randomized trial demonstrated the superiority ofClinical Lymphoma, Myeloma & Leukemia October 2015 - 589
Figure 5 Overall Survival According to Treatment With or
Without Rituximab-Containing Regimen
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590 -R-CHOP and R-FM over R-CVP in terms of response rates and time
to treatment failure (3-year time to treatment failure 60%, 57%, and
47%, respectively).26
After stratiﬁcation of our group of patients into rituximab
chemotherapy and chemotherapy-alone groups to determine the
impact on PFS of adding rituximab, the difference between the 2
treatments was signiﬁcant. The median PFS in our patients in
chemotherapy-alone arm was approximately 12 months, which is
quite short and even worse than in some of the aforementioned trials.
Marcus et al5 reported themedian time to progression in theCVP arm
to be 15 months, and Hiddemann et al8 reported a median PFS of 28
months but with the CHOP regimen, which is proven to be more
effective than nonanthracycline regimens. The short median PFS of
our patients is probably due to the fact thatmost in the chemotherapy-
alone group received nonanthracycline chemotherapy as front-line
treatment. For rituximab chemotherapy regimens, the median PFSs
are longer. For example, in the R-CVP group, the median time to
progression was 32months in one study,5 while in other studies where
R-CHOPwas provided, the median time has not yet been reached.8,9
This is similar to our analysis, with R-CHOP being by far the most
used induction regimen in the rituximab chemotherapy group, with a
median PFS that has not yet been reached. Actually, the risk for
progression in the rituximab chemotherapy group was reduced by
74% compared to the chemotherapy-only group (HR, 0.26; 95%CI,
0.18-0.36; P< .001). In the randomized study byHiddemann et al,8
which compared R-CHOPwithCHOP in front-line treatment, there
was a 60% reduction of risk for treatment failure (P< .001) in favor of
R-CHOP regimen. The data from the LymphoCare study conﬁrmR-
CHOP to be the most frequently used rituximab-based regimen in
front-line FL therapy, which has also become the standard of care for
front-line treatment.3
Some of the randomized studies mentioned above demonstrated a
signiﬁcant beneﬁt not only in terms of PFS but also OS whenClinical Lymphoma, Myeloma & Leukemia October 2015comparing rituximab chemotherapy with chemotherapy alone in
front-line treatment and in the relapse setting.5-8,27 Ameta-analysis of
7 randomized trials involving 1943 patients with previously untreated
or treated FL demonstrated that patients treated with rituximab-
containing regimens, compared to those treated with the same regi-
mens but without rituximab, had signiﬁcantly improved OS (HR,
0.63; 95% CI, 0.51-0.79).28 Herold et al7 randomized previously
untreated patients to R-MCP (rituximab, mitoxantrone, chlor-
ambucil, prednisolone) versus MCP with a 4-year follow-up differ-
ence in OS of 87% versus 74% in favor of R-MCP (P¼ .0096). In a
randomized study by Marcus et al,6 the patients in the R-CVP group
had signiﬁcantly higher rates of 4-year OS (83% vs. 77%; P¼ .029).
In addition, the study of Overman et al29 showed a beneﬁt in OS for
follicular grade 3 lymphoma patients, with R-CHOP chemotherapy
versus CHOP alone with a 5-year OS of 98% versus 75% in favor of
R-CHOP (P< .0034). In our analysis, no difference in OS between
the rituximab chemotherapy and chemotherapy-alone groups in ﬁrst-
line treatment was observed. The 5-year OS was 82% for the ritux-
imab chemotherapy group and 68% for the chemotherapy-alone
group (HR, 0.76; 95% CI, 0.45-1.27; P ¼ .29). The reason for
this lack of signiﬁcance inOS is probably that 63%of the patients who
did not receive rituximab and/or CHOP regimen in induction ther-
apy, crossed over to R-CHOP therapy subsequently at progression or
in case of relapsed disease. We have no data about howmany patients
crossed over to rituximab therapy in the previouslymentioned studies.
However, there was a signiﬁcant difference in the OS when we
compared the group of 163 patients who received rituximab-
containing therapy at least once during the course of their disease to
a small group of 30 FL patients who had never received rituximab as a
part of their ST (5-yearOS 79.2% vs. 50.8%). The risk of dying in the
rituximab group was actually reduced by 61% (HR, 0.39; 95% CI,
0.22-0.67; P ¼ .001).
The use of maintenance rituximab after immunochemotherapy
has been examined in several large randomized trials.10-15 Most of
them demonstrated a beneﬁcial effect by prolonging response
duration in ﬁrst remission and in patients with recurrent disease.
Hochster et al13 reported a signiﬁcantly better 3-year PFS of 64%
in the rituximab maintenance group compared to 33% in the
observation group after CVP induction chemotherapy (HR, 0.4;
P ¼ 9.2  108). Van Oers et al14 evaluated rituximab mainte-
nance in relapsed FL patients and demonstrated a signiﬁcantly
improved PFS after CHOP (HR, 0.30; P < .001) as well as after a
R-CHOP regimen (HR, 0.54; P ¼ .004). A meta-analysis of 9
randomized trials comparing rituximab maintenance with no
maintenance found a signiﬁcant PFS beneﬁt in the rituximab
maintenance arm and an improved OS in relapsed patients, whereas
the previously untreated patients had no survival beneﬁt (HR, 0.72;
95% CI, 0.57-0.91). This may be due to the longer follow-up
needed to demonstrate a survival difference of patients in ﬁrst
remission, whose estimated survival is almost 2 decades.30
The PRIMA study was the ﬁrst large phase 3 randomized trial to
investigate the potential beneﬁt of 2-year maintenance rituximab
therapy in previously untreated FL patients who responded to ﬁrst-
line immunochemotherapy. There were 1019 patients included.
With a median follow-up of 36 months from randomization, the
3-year PFS was 74.9% in the rituximab maintenance group
compared to 57.6% in the observation group (P < .0001). These
Tanja Juznic Setina et alresults demonstrated a signiﬁcant reduction of risk of progression,
with an HR of 0.55 (95% CI, 0.44-0.68; P < .0001) in favor of
patients randomized to rituximab maintenance.15 Our study can
fairly compare to the results of the PRIMA study though with less
patients included into analysis. The 3-year PFS of our patients was
77% in the maintenance group compared to 50% in the observa-
tion only group. There was a signiﬁcant reduction of risk of pro-
gression, with an HR of 0.39 (95% CI, 0.20-0.73; P < .003).
In conclusion, the results of our analysis can be related to the
results of several larger pivotal studies. Adding rituximab to com-
bination therapy in FL signiﬁcantly prolonged the PFS and OS of
these patients. Furthermore, rituximab maintenance therapy in ﬁrst-
line treatment signiﬁcantly prolongs the time to disease progression.
Clinical Practice Points
 The treatment outcomes of FL patients have been positively
inﬂuenced by the introduction of rituximab in the last 2 decades.
 Our retrospective analysis of PFS and OS in 278 routinely
treated Slovene FL patients conﬁrmed the signiﬁcant beneﬁt of
adding rituximab to chemotherapy and into the maintenance
setting outside clinical studies.
 Strict adherence to treatment recommendations and early
introduction of rituximab into routine treatment of FL patients
assures treatment results that can be related to the results of larger
pivotal studies.Acknowledgments
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